NEUROCRINE BIOSCIENCES INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
NEUROCRINE BIOSCIENCES INC (NBIX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $49.66 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-11
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $49.66, a 10.91% decline from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $55.74, a 23.35% increase from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $45.19, a 41.00% increase from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $32.05, a 28.81% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2025-12-31 | $49.66 10-K · filed 2026-02-11 |
| 2024-12-31 | $55.74 10-K · filed 2026-02-11 |
| 2023-12-31 | $45.19 10-K · filed 2026-02-11 |
| 2022-12-31 | $32.05 10-K · filed 2025-02-10 |
| 2021-12-31 | $45.02 10-K · filed 2024-02-09 |
| 2020-12-31 | $45.67 10-K · filed 2023-02-09 |
| 2019-12-31 | $41.74 10-K · filed 2022-02-11 |
| 2018-12-31 | $43.42 10-K · filed 2021-02-05 |
| 2017-12-31 | $25.11 10-K · filed 2020-02-07 |
| 2016-12-31 | $21.49 10-K · filed 2019-02-08 |
| 2015-12-31 | $23.24 10-K · filed 2018-02-13 |
| 2014-12-31 | $12.57 10-K · filed 2017-02-14 |
| 2013-12-31 | $6.55 10-K · filed 2016-02-11 |
| 2012-12-31 | $6.05 10-K · filed 2015-02-09 |
| 2011-12-31 | $4.14 10-K · filed 2014-02-11 |
| 2010-12-31 | $1.80 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |